Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Ecnoglutide cycle length: what human studies ran

Approved outside the USAHuman trial evidence
Short answer: there is no established Ecnoglutide cycle length, and we found no human studies that report one.

Treatment and follow-up in human studies

No human study durations are recorded.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Ecnoglutide combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Ecnoglutide cycle length?
No. We found no human studies that report a treatment duration for Ecnoglutide.
What is the longest human study of Ecnoglutide?
None is recorded.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Ecnoglutide dosing reference Full research page

References

  1. Ecnoglutide: First Approvals Drugs. 2026
  2. Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Lancet Diabetes Endocrinol. 2025
  3. Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial Nat Commun. 2026
  4. Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial Lancet Diabetes Endocrinol. 2025
  5. Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial Nat Commun. 2024
  6. Discovery of ecnoglutide - A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog Mol Metab. 2023
  7. Ecnoglutide (CID 162625103) PubChem. 2026
  8. Drugs@FDA application data queried through openFDA for ecnoglutide (no matching application record returned on 24 October 2026) openFDA / Drugs@FDA. 2026
  9. A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity (NCT05813795) ClinicalTrials.gov. 2026
  10. A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (NCT07073417) ClinicalTrials.gov. 2026
  11. A Study of XW003 Injection in Chinese Adolescents With Obesity (NCT07143227) ClinicalTrials.gov. 2026
  12. No dose adjustment required for warfarin or metformin when coadministered with the novel GLP-1 receptor agonist ecnoglutide: an open-label, fixed-sequence, crossover study Front Pharmacol. 2026
  13. International Standard: Prohibited List 2026 World Anti-Doping Agency. 2026